Skip to main content
    M

    MBX Biosciences, Inc. Common Stock (MBX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $50.71
    +1.89 (+3.87%)

    Market Cap: $2.35B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    75%(6/8)
    Avg Surprise
    +9.09%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.84
    Range$-0.96 - $-0.74
    7 analysts
    EPS RevisionsNo revisions (7d)
    0
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.74-14.4%
    60d ago$-0.74-14.4%
    30d ago$-0.840.0%
    7d ago$-0.840.0%
    Current$-0.84
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.02
    Range$-1.27 - $-0.88
    8 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.02---
    Sep 26EST
    		-$-0.84---
    Jun 26
    Reported Aug 6
    		$-0.78$-0.68-14.71%Miss-34.5%
    Mar 26
    Reported May 7
    		$-0.51$-0.58+12.07%Beat+28.2%
    Dec 25
    Reported Mar 12
    		$-0.49$-0.60+17.88%Beat-4.3%
    Sep 25
    Reported Nov 6
    		$-0.63$-0.68+7.35%Beat+77.3%
    Jun 25
    Reported Aug 7
    		$-0.58$-0.77+24.68%Beat+94.9%
    Mar 25
    Reported May 12
    		$-0.71$-0.77+7.79%Beat-
    Dec 24
    Reported Mar 17
    		$-0.47$-0.59+19.85%Beat-
    Sep 24
    Reported Nov 7
    		$-2.78$-2.72-2.21%Miss-
    Jun 24
    Reported Aug 23
    		$-11.47$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-21.04EV/EBITDAN/A
    Price/FCF-28.39xFCF Yield-3.52%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-33.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio18.08xQuick Ratio18.08x
    Trading Statistics
    Beta0.10Avg Volume634.64K
    52-Week High$72.6452-Week Low$12.94

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$53.55
    SMA 20$55.94
    SMA 50$61.08
    SMA 200$44.51
    EMA 10$52.74
    EMA 20$55.23
    EMA 50$57.60
    EMA 200$46.19

    MACD

    Line: -2.92Signal: -2.28Hist: -0.64

    ADX

    ADX: 27.6+DI: 13.5-DI: 28.9

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down96.0
    PSAR$55.63

    Bollinger Bands

    Upper Band$63.95
    Lower Band$47.92
    %B Position2866%(Upper)
    Band Width0.17

    RSI (14-Day)

    Neutral
    35.3

    Momentum Oscillators

    Stoch %K10.9
    Stoch %D10.3
    Williams %R-77.0
    ROC (10d)-10.3%
    Momentum-5.84
    CCI (20d)-121.6
    MFI (14d)39.7

    Volatility Measures

    ATR (14d)$3.28(6.5%)
    StdDev (20d)4.01
    Hist Vol55.0%(High)

    Volume Flow

    VWAP$50.20
    OBV46.1M
    AD Line-4.6M
    CMF (20d)-0.121

    Volume Metrics

    Avg Vol (20d)591.6K
    Vol Ratio1.0x
    VWMA (20d)$55.66

    Pivot Points

    R3$51.65
    R2$50.59
    R1$49.71
    Pivot Point$48.65
    S1$47.77
    S2$46.71
    S3$45.83

    Advanced Oscillators

    TSI-27.45
    Ultimate Osc43.5
    KST-136.91

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$222,000$0$0$0$0$0
    Cost of Revenue$0$0$60,000$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0$-60,000$0$0$0$111,000$0$0$0N/A$0
    Operating Expenses$40.93M$27.27M$25.80M$23.93M$21.80M$26.53M$18.61M$19.61M$16.66M$13.31M$9.99M$10.95M
    R&D$30.98M$18.47M$19.76M$19.27M$17.72M$22.41M$15.22M$16.75M$14.40M$11.05M$7.73M$9.07M
    SG&A$9.95M$8.79M$6.04M$4.66M$4.08M$4.12M$3.39M$2.87M$2.26M$2.27M$2.26M$1.87M
    Operating Income$-40,931,000$-27,265,000$-25,795,000$-23,926,000$-21,805,000$-26,529,000$-18,610,000$-19,612,000$-16,658,000$-13,314,000$-9,991,000$-10,945,000
    Interest Income$3.84M$3.75M$3.73M$2.31M$2.39M$2.65M$3.02M$1.47M$801,000$977,000$1.15M$783,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-37,095,000$-23,517,000$-22,062,000$-21,618,000$-19,411,000$-23,880,000$-15,586,000$-18,142,000$-15,857,000$-12,337,000$-8,843,000$-10,162,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-37,095,000$-23,517,000$-22,062,000$-21,618,000$-19,411,000$-23,880,000$-15,586,000$-18,142,000$-15,857,000$-12,337,000$-8,843,000$-10,162,000
    EBITDA$-41,273,000$-27,780,000$-26,290,000$-24,610,000$-22,723,000$-27,795,000$-19,949,000$-20,124,000$-17,036,000$-13,769,000$-7,202,000$-10,945,000
    EBIT$-40,931,000$-27,265,000$-25,795,000$-23,926,000$-21,805,000$-26,529,000$-18,610,000$-19,612,000$-16,658,000$-13,314,000$-7,243,000$-10,945,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MBX

    News

    MBX Biosciences to Participate in Upcoming November Investor Conferences

    MBX Biosciences announced that its CEO, Steve Hoerter, and CMO, Sam Azoulay, M.D., will participate in three upcoming investor conferences in November 2026. These include the Guggenheim 3rd Annual Healthcare Innovation...

    GlobeNewswire•10/13/26•Somewhat-Bullish

    MBX Biosciences, Inc. (MBX) Stock Price, News, Quote & History

    MBX Biosciences, Inc. (MBX) is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. The company's stock is currently trading at $48.82...

    Yahoo Finance•10/13/26•Somewhat-Bullish

    MBX Biosciences to Participate in Upcoming November Investor Conferences

    MBX Biosciences announced its participation in three upcoming investor conferences in November 2026: the Guggenheim 3rd Annual Healthcare Innovation Conference, the UBS Global Biopharma Conference...

    GlobeNewswire•10/13/26•Somewhat-Bullish

    MBX Biosciences to Participate in Upcoming November Investor Conferences

    MBX Biosciences, a clinical-stage biopharmaceutical company, announced that its Chairman and CEO, Steve Hoerter, and Chief Medical Officer, Sam Azoulay, M.D....

    Yahoo Finance•10/13/26•Somewhat-Bullish

    Stifel raises MBX Biosciences price target to $84 on obesity drug data

    Stifel increased its price target for MBX Biosciences (NASDAQ:MBX) to $84 from $70, maintaining a Buy rating, based on upcoming Part-C data from its Phase 1 trial for obesity drug MBX-4291. The drug...

    Investing.com Nigeria•10/12/26•Bullish

    MBX Valuation and Fair Value

    P/E
    -21.0x
    P/FCF
    -28.4x
    P/B
    5.9x
    See GNG's fair value

    MBX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -33.2%
    FCF yield
    -3.5%

    MBX Competitors

    CompanyTicker
    Maravai Lifesciences Holdings IncMRVI
    HUTCHMED DRCHCM
    Beam Therapeutics IncBEAM
    89bio IncETNB
    Sellas Life Sciences Group IncSLS
    Supernus Pharmaceuticals IncSUPN
    Zai Lab LtdZLAB
    Prestige Brand Holdings IncPBH

    Sector: Healthcare

    MBX Analyst Ratings

    Consensus
    Buy
    Analysts
    11
    Strong Buy
    3
    Buy
    8
    Hold
    0
    Sell
    0
    Strong Sell
    0

    MBX Bull Case vs Bear Case

    Bull case

    • MBX beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 100.0% of MBX's analyst ratings are Buy or Strong Buy.

    MBX Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    9.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.84
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 4 down

    Frequently Asked Questions About MBX

    Does MBX pay dividends?

    MBX Biosciences, Inc. Common Stock (MBX) does not currently pay a regular dividend.

    What is MBX's market cap?

    MBX Biosciences, Inc. Common Stock (MBX) has a market capitalization of $2.35B with a current stock price of $50.71.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In